Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives
- PMID: 11435802
- DOI: 10.1097/00004691-200103000-00002
Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives
Abstract
Narcolepsy is characterized by excessive daytime sleepiness and abnormal manifestations of rapid eye movement sleep such as cataplexy. The authors review the clinical features of narcolepsy, including epidemiology, symptoms, diagnosis, and treatment, in detail. Recent findings show that a loss of hypocretin-producing neurons lies at the root of the signs and symptoms of narcolepsy. The authors review the current state of knowledge on hypocretin anatomy, physiology, and function with special emphasis on the research regarding the hypocretin deficiency in narcolepsy, which may also explain associated features of the disorder, such as obesity. Lastly, they discuss some future perspectives for research into the pathophysiology of sleep/wake disorders, and the potential impact of the established hypocretin deficiency on the diagnosis and treatment of narcolepsy.
Similar articles
-
Narcolepsy: pathophysiology and pharmacology.J Clin Psychiatry. 2007;68 Suppl 13:9-15. J Clin Psychiatry. 2007. PMID: 18078360 Review.
-
Hypocretin (orexin) deficiency predicts severe objective excessive daytime sleepiness in narcolepsy with cataplexy.J Neurol Neurosurg Psychiatry. 2006 Mar;77(3):402-4. doi: 10.1136/jnnp.2005.067207. J Neurol Neurosurg Psychiatry. 2006. PMID: 16484654 Free PMC article.
-
Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system.Sleep Med Rev. 2005 Aug;9(4):269-310. doi: 10.1016/j.smrv.2005.03.004. Sleep Med Rev. 2005. PMID: 16006155 Review.
-
Parkinsonism with excessive daytime sleepiness--a narcolepsy-like disorder?J Neurol. 2005 Feb;252(2):139-45. doi: 10.1007/s00415-005-0614-5. J Neurol. 2005. PMID: 15729517
-
Pediatric narcolepsy.Brain Dev. 2008 Nov;30(10):609-23. doi: 10.1016/j.braindev.2008.02.004. Epub 2008 Mar 28. Brain Dev. 2008. PMID: 18375081 Review.
Cited by
-
Sodium oxybate: a review of its use in the management of narcolepsy.CNS Drugs. 2007;21(4):337-54. doi: 10.2165/00023210-200721040-00007. CNS Drugs. 2007. PMID: 17381187 Review.
-
Expression of a poly-glutamine-ataxin-3 transgene in orexin neurons induces narcolepsy-cataplexy in the rat.J Neurosci. 2004 May 5;24(18):4469-77. doi: 10.1523/JNEUROSCI.5560-03.2004. J Neurosci. 2004. PMID: 15128861 Free PMC article.
-
Orexin/hypocretin and dysregulated eating: Promotion of foraging behavior.Brain Res. 2020 Mar 15;1731:145915. doi: 10.1016/j.brainres.2018.08.018. Epub 2018 Aug 17. Brain Res. 2020. PMID: 30125533 Free PMC article. Review.
-
Hypothalamic MCH Neuron Activity Dynamics during Cataplexy of Narcolepsy.eNeuro. 2020 Apr 29;7(2):ENEURO.0017-20.2020. doi: 10.1523/ENEURO.0017-20.2020. Print 2020 Mar/Apr. eNeuro. 2020. PMID: 32303567 Free PMC article.
-
Neuropeptides controlling energy balance: orexins and neuromedins.Handb Exp Pharmacol. 2012;(209):77-109. doi: 10.1007/978-3-642-24716-3_4. Handb Exp Pharmacol. 2012. PMID: 22249811 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources